Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation ( Joint Asia Diabetes Evaluation (JADE) ) register
Authors' conclusion
In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D.
Study context
- Population
- Adults with T2D from 11 Asian countries/regions enrolled in the prospective JADE register, November 2007–December 2019; patients receiving insulin and/or injectable GLP-1 RA excluded; mean age 57.3 ± 11.8 years, 53.6% men
- Participants
- 62,512 adults
- Exposure
- Gliclazide vs non-gliclazide SU users
- Outcome
- Patterns of OGLD use
- Follow-up
- Enrolment
Methodological detailsJADE register, 11 Asian countries/regions
- JADE register
- 11 Asian countries/regions
Main finding
As reported in the abstract
- Treated with oral glucose-lowering drugs (OGLDs) at enrolment
- 54 783 (87.6%)
- Received one OGLD
- 37.5%
- Received two OGLDs
- 44.2%
- Treated patients receiving SU-based therapy, with variations amongst countries/regions
- 59.4%
- SU regimens based on SUs plus metformin
- 79.5%
- SU regimens based on SUs plus DPP-4i
- 22.1%
- Gliclazide among SU users
- 46.7%
- Glimepiride among SU users
- 40.0%
- Glibenclamide among SU users
- 8.1%
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| HbA1c <53 mmol/mol (7%) at entry · enrolment | 1.09 (1.02–1.17) | |
| 0.512Odds ratio (log scale) |
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Self-reported hypoglycaemia in the 3 months before registration | 0.81 (0.72–0.92) | |
| 0.512Odds ratio (log scale) |
- Self-reported hypoglycaemia in the 3 months before registration: adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration
Original publication
Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation ( JADE ) register. Diabetes Obes Metab. Published 26 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →